Applied Therapeutics, Inc. (APLT)

$ 3.42
-0.16 (-4.47%)
-
Symbol APLT
Price $ 3.42
Beta 0.904
Volume Avg. 0.26M
Market Cap 0.090B
Shares () -
52 Week Range 3.39-29.8
1y Target Est -
DCF Unlevered APLT DCF ->
DCF Levered APLT LDCF ->
ROE -98.12% Strong Sell
ROA -86.14% Strong Sell
Operating Margin -
Debt / Equity 36.73% Neutral
P/E -
P/B 1.03 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest APLT news


Dr. Shoshana Shendelman Ph.D.
Healthcare
Biotechnology
Nasdaq Global Market

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.